158 related articles for article (PubMed ID: 7768001)
21. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides.
Agrawal S
Biochim Biophys Acta; 1999 Dec; 1489(1):53-68. PubMed ID: 10806997
[TBL] [Abstract][Full Text] [Related]
22. Self-stabilized antisense oligodeoxynucleotide phosphorothioates: properties and anti-HIV activity.
Tang JY; Temsamani J; Agrawal S
Nucleic Acids Res; 1993 Jun; 21(11):2729-35. PubMed ID: 8392706
[TBL] [Abstract][Full Text] [Related]
23. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide.
Temsamani J; Roskey A; Chaix C; Agrawal S
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):159-65. PubMed ID: 9212906
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of HIV-1 in vitro by C-5 propyne phosphorothioate antisense to rev.
Lund OS; Nielsen JO; Hansen JE
Antiviral Res; 1995 Sep; 28(1):81-91. PubMed ID: 8585762
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration.
Phillips JA; Craig SJ; Bayley D; Christian RA; Geary R; Nicklin PL
Biochem Pharmacol; 1997 Sep; 54(6):657-68. PubMed ID: 9310342
[TBL] [Abstract][Full Text] [Related]
26. Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey.
Yu RZ; Geary RS; Leeds JM; Watanabe T; Moore M; Fitchett J; Matson J; Burckin T; Templin MV; Levin AA
J Pharm Sci; 2001 Feb; 90(2):182-93. PubMed ID: 11169535
[TBL] [Abstract][Full Text] [Related]
27. Effect of aspirin on protein binding and tissue disposition of oligonucleotide phosphorothioate in rats.
Agrawal S; Zhang X; Cai Q; Kandimalla ER; Manning A; Jiang Z; Marcel T; Zhang R
J Drug Target; 1998; 5(4):303-12. PubMed ID: 9713979
[TBL] [Abstract][Full Text] [Related]
28. Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides modulate CYP2B1 expression in vivo.
Desjardins J; Mata J; Brown T; Graham D; Zon G; Iversen P
J Drug Target; 1995; 2(6):477-85. PubMed ID: 7773609
[TBL] [Abstract][Full Text] [Related]
29. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies.
Agrawal S; Jiang Z; Zhao Q; Shaw D; Cai Q; Roskey A; Channavajjala L; Saxinger C; Zhang R
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2620-5. PubMed ID: 9122245
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics, biodistribution, and stability of capped oligodeoxynucleotide phosphorothioates in mice.
Temsamani J; Tang JY; Padmapriya A; Kubert M; Agrawal S
Antisense Res Dev; 1993; 3(3):277-84. PubMed ID: 8286928
[TBL] [Abstract][Full Text] [Related]
31. Renal uptake of an 18-mer phosphorothioate oligonucleotide.
Oberbauer R; Schreiner GF; Meyer TW
Kidney Int; 1995 Oct; 48(4):1226-32. PubMed ID: 8569084
[TBL] [Abstract][Full Text] [Related]
32. Use of cyclodextrin and its derivatives as carriers for oligonucleotide delivery.
Zhao Q; Temsamani J; Agrawal S
Antisense Res Dev; 1995; 5(3):185-92. PubMed ID: 8785474
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats.
Cossum PA; Truong L; Owens SR; Markham PM; Shea JP; Crooke ST
J Pharmacol Exp Ther; 1994 Apr; 269(1):89-94. PubMed ID: 8169856
[TBL] [Abstract][Full Text] [Related]
34. Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate oligonucleotide ISIS 1082 in rat.
Peng B; Andrews J; Nestorov I; Brennan B; Nicklin P; Rowland M
Antisense Nucleic Acid Drug Dev; 2001 Feb; 11(1):15-27. PubMed ID: 11258618
[TBL] [Abstract][Full Text] [Related]
35. Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys.
Yu RZ; Geary RS; Monteith DK; Matson J; Truong L; Fitchett J; Levin AA
J Pharm Sci; 2004 Jan; 93(1):48-59. PubMed ID: 14648635
[TBL] [Abstract][Full Text] [Related]
36. In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue.
Iversen P
Anticancer Drug Des; 1991 Dec; 6(6):531-8. PubMed ID: 1772568
[TBL] [Abstract][Full Text] [Related]
37. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides.
Geary RS; Leeds JM; Henry SP; Monteith DK; Levin AA
Anticancer Drug Des; 1997 Jul; 12(5):383-93. PubMed ID: 9236854
[No Abstract] [Full Text] [Related]
38. Oligoradionuclidetherapy using radiolabelled antisense oligodeoxynucleotide phosphorothioates.
Kairemo KJ; Tenhunen M; Jekunen AP
Anticancer Drug Des; 1996 Sep; 11(6):439-49. PubMed ID: 8836109
[TBL] [Abstract][Full Text] [Related]
39. Dosimetry of radionuclide therapy using radiophosphonated antisense oligodeoxynucleotide phosphorothioates based on animal pharmacokinetic and tissue distribution data.
Kairemo KJ; Tenhunen M; Jekunen AP
Antisense Nucleic Acid Drug Dev; 1996; 6(3):215-20. PubMed ID: 8915506
[TBL] [Abstract][Full Text] [Related]
40. Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2'-O-methyl phosphodiester oligonucleotides in normal rats.
Lendvai G; Velikyan I; Bergström M; Estrada S; Laryea D; Välilä M; Salomäki S; Långström B; Roivainen A
Eur J Pharm Sci; 2005 Sep; 26(1):26-38. PubMed ID: 15941654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
